Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

137.41USD
15 Dec 2017
Change (% chg)

$1.63 (+1.20%)
Prev Close
$135.78
Open
$136.28
Day's High
$138.32
Day's Low
$135.41
Volume
681,329
Avg. Vol
198,979
52-wk High
$169.58
52-wk Low
$112.15

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $5,937.63
Shares Outstanding(Mil.): 43.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

Nov 14 2017

BRIEF-United Therapeutics Corp reports third quarter 2017 financial results

* United Therapeutics Corporation reports third quarter 2017 financial results

Oct 25 2017

BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

Oct 23 2017

BRIEF-United Therapeutics Corp reports Q2 EPS non-GAAP $4.37

* United Therapeutics Corporation reports second quarter 2017 financial results

Jul 27 2017

Earnings vs. Estimates